UY34999A - Formulaciones de anticuerpos anti-receptor de prolactina - Google Patents

Formulaciones de anticuerpos anti-receptor de prolactina

Info

Publication number
UY34999A
UY34999A UY0001034999A UY34999A UY34999A UY 34999 A UY34999 A UY 34999A UY 0001034999 A UY0001034999 A UY 0001034999A UY 34999 A UY34999 A UY 34999A UY 34999 A UY34999 A UY 34999A
Authority
UY
Uruguay
Prior art keywords
prolactin
formulations
receiver
antibodies anti
free
Prior art date
Application number
UY0001034999A
Other languages
English (en)
Inventor
Ma Xinghang
Xiang Jun
Niu Jianjie
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of UY34999A publication Critical patent/UY34999A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcion an formulaciones de anticuerpos anti-receptor de prolactina de amplio intervalo de concentración, especialmente de alta concentración,sustancialmente sin sal que son sustancialmente isosmóticas y de baja viscosidad
UY0001034999A 2012-08-31 2013-08-30 Formulaciones de anticuerpos anti-receptor de prolactina UY34999A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695949P 2012-08-31 2012-08-31
US13/842,906 US8883979B2 (en) 2012-08-31 2013-03-15 Anti-prolactin receptor antibody formulations

Publications (1)

Publication Number Publication Date
UY34999A true UY34999A (es) 2014-03-31

Family

ID=49162240

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001034994A UY34994A (es) 2012-08-31 2013-08-29 Formulaciones de anticuerpo anti receptor de prolactina
UY0001034999A UY34999A (es) 2012-08-31 2013-08-30 Formulaciones de anticuerpos anti-receptor de prolactina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY0001034994A UY34994A (es) 2012-08-31 2013-08-29 Formulaciones de anticuerpo anti receptor de prolactina

Country Status (30)

Country Link
US (4) US8883979B2 (es)
EP (1) EP2890397B1 (es)
JP (1) JP6444871B2 (es)
KR (1) KR102100282B1 (es)
CN (3) CN111202844A (es)
AR (2) AR092387A1 (es)
AU (1) AU2013308907B2 (es)
BR (1) BR112015004397B1 (es)
CA (1) CA2883097C (es)
CY (1) CY1121990T1 (es)
DK (1) DK2890397T3 (es)
ES (1) ES2742868T3 (es)
HK (1) HK1207316A1 (es)
HR (1) HRP20191199T1 (es)
HU (1) HUE045494T2 (es)
IL (1) IL237277B (es)
IN (1) IN2015DN02255A (es)
LT (1) LT2890397T (es)
MX (1) MX367691B (es)
NZ (1) NZ705178A (es)
PL (1) PL2890397T3 (es)
PT (1) PT2890397T (es)
RS (1) RS59207B1 (es)
RU (1) RU2649372C2 (es)
SG (1) SG11201501225SA (es)
SI (1) SI2890397T1 (es)
TW (3) TW201422235A (es)
UY (2) UY34994A (es)
WO (1) WO2014036076A1 (es)
ZA (1) ZA201501279B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687974T3 (es) 2012-03-14 2018-10-30 Regeneron Pharmaceuticals, Inc. Moléculas multiespecíficas de unión a antígeno y uso de las mismas
CN105102480B (zh) 2012-12-24 2019-04-16 艾伯维公司 催乳素受体结合蛋白及其用途
JP2016515515A (ja) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 抗プロラクチン受容体抗体製剤
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN107249571B (zh) * 2015-02-09 2021-03-12 Ucb生物制药私人有限公司 药物制剂
MY197218A (en) 2015-07-06 2023-06-02 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
JP6720293B2 (ja) 2015-08-19 2020-07-08 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 安定な抗ｉｆｎａｒ１製剤
WO2017057644A1 (ja) * 2015-09-30 2017-04-06 持田製薬株式会社 高濃度抗体含有液体製剤
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
CN110382534B (zh) 2016-11-29 2023-05-09 里珍纳龙药品有限公司 治疗prlr阳性乳腺癌的方法
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JPWO2018179138A1 (ja) * 2017-03-29 2020-02-06 持田製薬株式会社 抗体含有液体製剤
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
BR112019021364A2 (pt) * 2017-04-11 2020-05-05 Kiniksa Phamaceuticals Ltd formulação estável de anticorpo anti-osmr
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
CA3069193A1 (en) 2017-07-10 2019-01-17 Bayer Pharma Aktiengesellschaft Prolactin receptor antibody for male and female pattern hair loss
KR20200089282A (ko) * 2017-11-20 2020-07-24 저스트-에보텍 바이오로직스, 아이엔씨. 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
BR112020016005A2 (pt) 2018-02-07 2020-12-15 Regeneron Pharmaceuticals, Inc. Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio
BR112021004649A2 (pt) * 2018-09-13 2021-06-01 F. Hoffmann-La Roche Ag formulação farmacêutica e uso de uma formulação
SG11202103907PA (en) * 2018-10-18 2021-05-28 Merck Sharp & Dohme Formulations of anti-rsv antibodies and methods of use thereof
US20210395352A1 (en) * 2018-10-30 2021-12-23 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2023230532A1 (en) * 2022-05-26 2023-11-30 Compugen Ltd. Anti-tigit antibody formulation

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
DE69810481T2 (de) 1997-06-13 2003-09-25 Genentech Inc Stabilisierte antikörperformulierung
AU2444899A (en) 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
PT1491208E (pt) 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Composições farmacêuticas contendo polipéptido líquidas estabilizadas
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
EP1517698B2 (en) 2002-06-21 2017-12-06 Novo Nordisk Health Care AG STABILISED SOLID COMPOSITIONS OF FACTOR VIIa POLYPEPTIDES
CN1751236A (zh) * 2002-12-16 2006-03-22 健泰科生物技术公司 表达人cd20的转基因小鼠
MY162623A (en) 2003-02-10 2017-06-30 Biogen Ma Inc Immunoglobulin formulation and method of preparation thereof
JP2006524195A (ja) 2003-03-18 2006-10-26 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液状水性医薬組成物
CN101818138A (zh) 2003-03-18 2010-09-01 诺和诺德医疗保健公司 生产含有gla残基的丝氨酸蛋白酶的方法
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EA009285B1 (ru) 2003-05-14 2007-12-28 Иммуноджен, Инк. Композиция конъюгированного лекарственного средства
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2004103398A1 (en) 2003-05-23 2004-12-02 Novo Nordisk Health Care Ag Protein stabilization in solution
JP4658041B2 (ja) 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
ATE446768T1 (de) 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
AU2004277466C1 (en) 2003-10-01 2022-06-23 Kyowa Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
DE10361599A1 (de) 2003-12-24 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Flüssigformulierung von Antikörperkonjugaten
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
DE102004022927A1 (de) 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
WO2006014965A2 (en) 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008519032A (ja) * 2004-11-03 2008-06-05 キュラジェン コーポレイション Ｆｇｆ−２０の調合物、生成方法および使用
DE102005002353A1 (de) * 2005-01-18 2006-07-27 Abbott Gmbh & Co. Kg AGER-Rezeptor Multimerisierungs Epitope
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
EP1893647A2 (en) * 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
EP2377554A1 (en) 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
CA2642270A1 (en) 2006-02-15 2007-08-23 Imclone Systems Incorporated Antibody formulation
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
PT2059535E (pt) * 2006-08-18 2014-01-29 Novartis Ag Anticorpos específicos do prlr e suas utulizações
US20100129379A1 (en) 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
ES2748526T3 (es) 2006-12-21 2020-03-17 Amgen Inc Formulaciones tamponadas estables que contienen polipéptidos
US20100143326A1 (en) 2007-01-03 2010-06-10 Novo Nordisk Healthcare A/G SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES
MX2009011408A (es) 2007-05-02 2009-11-05 Hoffmann La Roche Metodo para estabilizar una proteina.
EP2173163A4 (en) 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
MX2010001723A (es) 2007-08-17 2010-04-30 Amgen Inc Formulaciones de anticuerpos y moleculas de fusion-fc usando policationes.
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ602498A (en) 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
PT2234600E (pt) * 2007-12-21 2014-09-25 Hoffmann La Roche Formulação de anticorpos
JP2011506565A (ja) * 2007-12-21 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8486892B2 (en) 2008-01-23 2013-07-16 Novo Nordisk Health Care Ag Blood coagulation factor inhibitors
CN102281903B (zh) 2008-11-17 2013-11-13 弗·哈夫曼-拉罗切有限公司 降低大分子在生理条件下聚集的方法和配方
NZ592644A (en) * 2008-11-28 2013-09-27 Abbott Lab Stable antibody compositions and methods for stabilizing same
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
NZ595694A (en) * 2009-05-04 2013-09-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
MY158130A (en) * 2010-10-06 2016-08-30 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor )il-4r) antibodies

Also Published As

Publication number Publication date
DK2890397T3 (da) 2019-08-05
RU2015111319A (ru) 2016-10-20
BR112015004397A2 (pt) 2017-12-19
PL2890397T3 (pl) 2019-12-31
HRP20191199T1 (hr) 2019-10-18
CN104736175B (zh) 2019-11-01
PT2890397T (pt) 2019-09-10
CN111202844A (zh) 2020-05-29
TW201821103A (zh) 2018-06-16
JP6444871B2 (ja) 2018-12-26
ES2742868T3 (es) 2020-02-17
MX367691B (es) 2019-09-02
TW201414491A (zh) 2014-04-16
AR092401A1 (es) 2015-04-22
MX2015002412A (es) 2015-09-29
HK1207316A1 (en) 2016-01-29
IL237277A0 (en) 2015-04-30
EP2890397A1 (en) 2015-07-08
US20140065158A1 (en) 2014-03-06
US20150252116A1 (en) 2015-09-10
TW201422235A (zh) 2014-06-16
CA2883097A1 (en) 2014-03-06
SG11201501225SA (en) 2015-03-30
BR112015004397B1 (pt) 2022-07-19
CN111202843A (zh) 2020-05-29
HUE045494T2 (hu) 2019-12-30
KR20150046298A (ko) 2015-04-29
AR092387A1 (es) 2015-04-22
AU2013308907A1 (en) 2015-03-12
WO2014036076A1 (en) 2014-03-06
IN2015DN02255A (es) 2015-08-21
CY1121990T1 (el) 2020-10-14
UY34994A (es) 2014-03-31
EP2890397B1 (en) 2019-06-19
RU2649372C2 (ru) 2018-04-02
TWI688404B (zh) 2020-03-21
US20170008965A1 (en) 2017-01-12
AU2013308907B2 (en) 2018-04-19
IL237277B (en) 2020-04-30
NZ705178A (en) 2018-06-29
CN104736175A (zh) 2015-06-24
US8883979B2 (en) 2014-11-11
CA2883097C (en) 2022-11-15
SI2890397T1 (sl) 2019-11-29
RS59207B1 (sr) 2019-10-31
US20150093393A1 (en) 2015-04-02
LT2890397T (lt) 2019-09-25
KR102100282B1 (ko) 2020-04-13
TWI641384B (zh) 2018-11-21
ZA201501279B (en) 2016-11-30
JP2015528465A (ja) 2015-09-28

Similar Documents

Publication Publication Date Title
UY34999A (es) Formulaciones de anticuerpos anti-receptor de prolactina
CL2015000582A1 (es) Anticuerpos anti-mcam y métodos asociados de uso
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CL2018000479A1 (es) Linfoopeitina strimal tomica (tslp) - anticuerpos de union y metodos de uso de los anticuerpos
BR112014019331A8 (pt) anticorpos para cd47 e métodos de uso desses
EA201592213A1 (ru) Антитела антирецептор трансферрина и способы их использования
CL2015002357A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
UY35460A (es) Formulaciones de anticuerpos anti-receptor de prolactina
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
CO6721041A2 (es) Anticuerpo anti-pcsk9 y métodos de uso
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
CR20150329A (es) Inmunoglobulinas heterodiméricas
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
BR112015018851A2 (pt) anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos
UY34815A (es) Anticuerpos biespecíficos y sus métodos de uso
ECSP14028523A (es) Moléculas de anticuerpo anti-gcc y uso de las mismas
MX2014014376A (es) Anticuerpos de anti-biotina y metodos de uso.
CR20150668A (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
ECSP13012536A (es) Composiciones de anticuerpo y métodos de uso
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
MA43464B1 (fr) Anticorps anti-cd3 et méthodes d'utilisation

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20220614